tbuckley/cabot-search huggingface dataset:
Intraductal papillary mucinous neoplasm of the Santorini duct in a patient with pancreas divisum diagnosed by transpapillary biopsy
Authors: Franz Singhartinger, Martin Varga, Antonia Gantschnigg, Andrej Wagner, Oliver Koch, Klaus Emmanuel, Josef Holzinger
Journal: Endoscopy (2022)

A 76-year-old patient presented with pancreatic duct dilatation on magnetic resonance imaging (MRI). The patient had no symptoms and no previous history of hepatobiliary or pancreatic disease. Endosonography showed pancreatic duct dilatation (12 mm) in the pancreatic body and tail. The pancreatic duct in the pancreatic head was only moderately dilated (5 mm).
The Quick Physical Exam
Authors: Robert E. Hirschtick
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
IRF1 is a Major Regulatory Transcription Factor for Type 2 and Type 1 Immune Responses in Eosinophils
Authors: Alissa Lynch, Christopher Nazaroff, Melanie Kienzl, William LeSuer, Alfred Doyle, Benjamin Wright, Matthew Rank, Alexander Krupnick, Elizabeth Jacobsen
Journal: Journal of Allergy and Clinical Immunology (2022)
Sex Education in High Schools
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Empire Rheumatism Council: Fifth Annual Report
Journal: Annals of the Rheumatic Diseases (1941)

This is the third year in succession that I shall not have the pleasure of meeting you for discussion of the Annual Report.I regret the long lapse, for there is nothing more valuable to an organisation such.asours than personal contact and free debate among members.But it was considered inadvisable under war conditions to make demands on your time and on transport services by calling members of the Council to London.I
Serum cholesterol levels in the medical community
Authors: W. L. Warner
Journal: JAMA (1968)

<h3>To the Editor:—</h3> Many investigators<sup>1-5</sup>have shown that the risk of a clinical episode of coronary artery disease is closely correlated with serum cholesterol levels. These epidemiologic studies show that the hypercholesterolemic population has a three to five times greater risk of coronary heart disease (CHD) than the normocholesterolemic population. Recognition of this important correlation has generated efforts to screen large population groups for elevated cholesterol levels. It is an interesting observation that physicians and their families are seldom included in local health programs. Because of this it seemed particularly appropriate to carry out a cholesterol-screening program exclusively for physicians and their guests at medical conventions. Accordingly, Flint Laboratories carried out such a program at eight medical meetings, beginning with the American Medical Association convention, 1967, and ending with the AMA convention, 1968. The screening program included 2,973 individuals, who were selected for no reason other than their presence
Breast-Cancer Risk in Families with Mutations in <i>PALB2</i>
Authors: Victoria Sopik, Steven A Narod
Journal: New England Journal of Medicine (2014)

Germline loss-of-function mutations in PALB2 are known to confer a predisposition to breast cancer.However, the lifetime risk of breast cancer that is conferred by such mutations remains unknown. METHODSWe analyzed the risk of breast cancer among 362 members of 154 families who had deleterious truncating, splice, or deletion mutations in PALB2.The age-specific breast-cancer risk for mutation carriers was estimated with the use of a modified segregation-analysis approach that allowed for the effects of PALB2 genotype and residual familial aggregation. RESULTSThe risk of breast cancer for female PALB2 mutation carriers, as compared with the general population, was eight to nine times as high among those younger than 40 years of age, six to eight times as high among those 40 to 60 years of age, and five times as high among those older than 60 years of age.The estimated cumulative risk of breast cancer among female mutation carriers was 14% (95% confidence interval [CI], 9 to 20) by 50 years of age and 35% (95% CI, 26 to 46) by 70 years of age.Breast-cancer risk was also significantly influenced by birth cohort (P < 0.001) and by other familial factors (P = 0.04).The absolute breast-cancer risk for PALB2 female mutation carriers by 70 years of age ranged from 33% (95% CI, 25 to 44) for those with no family history of breast cancer to 58% (95% CI, 50 to 66) for those with two or more first-degree relatives with breast cancer at 50 years of age. CONCLUSIONSLoss-of-function mutations in PALB2 are an important cause of hereditary breast cancer, with respect both to the frequency of cancer-predisposing mutations and to the risk associated with them.Our data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA2 mutation carriers.
Critical Care Medicine
Authors: Joseph E. Parrillo
Journal: JAMA (1992)

Seven years ago, in the 1985 version of the Contempo series, I raised the question about whether critical care medicine had evolved sufficiently to be designated a true medical subspecialty.<sup>1</sup>The present statistics strongly support that it has. Critical care board certification examinations have been given since 1986 or 1987 in the four specialties of anesthesiology, internal medicine, pediatrics, and surgery. Through 1991, more than 4600 physicians have attained full certification, with the majority (&gt;2800) coming from internal medicine.<sup>2</sup>The total number of approved fellowship training programs has risen to 196, with internal medicine accounting for more than 100 of these programs. Within the field of internal medicine, critical care subspecialty training is represented as follows: pulmonary (70%), only critical care medicine (16%), cardiology (9%), nephrology (4%), and infectious disease (1%). As "grandfathering" accounted for most of the candidates for these examinations, this representation will probably change somewhat
W. W. GERHARD, TYPHOID vs. TYPHUS FEVER
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Global reporting on tuberculosis preventive treatment among contacts
Authors: Dennis Falzon, Saskia den Boon, Avinash Kanchar, Matteo Zignol, Giovanni Battista Migliori, Tereza Kasaeva
Journal: European Respiratory Journal (2022)

<b>Country reports to WHO show low TB preventive treatment (TPT) coverage in contacts of people with TB, below global targets. More efforts are needed to find and evaluate TB contacts, help them access better regimens and complete TPT.</b>https://bit.ly/3sp0FA3
CRITICAL AIRWAY OBSTRUCTION
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: MATTHEW B. LUBIN
Journal: JNCI Journal of the National Cancer Institute (1991)

BOOK REVIEWS Get access Hereditary Cancer and Peventive Surgery. Walter Weber, Urban Laffer, Michael Dürig, eds. Basel: S. Karger, 1990. 118 pp.,illus. $72.75. MATTHEW B. LUBIN MATTHEW B. LUBIN Medical Genetics Strang Cancer Prevention Center The New York Hospital-Cornell Medical Center428 East 72nd St. New York, NY 10021 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 24, 18 December 1991, Pages 1829–1830, https://doi.org/10.1093/jnci/83.24.1829-a Published: 18 December 1991
Esthetic complications in implant dentistry
Authors: Ausra Ramanauskaite, Robert Sader
Journal: Periodontology 2000 (2022)

Abstract Esthetic complications in implant dentistry have become a significant consideration for patients and practitioners. This review presents an appraisal on the current knowledge of the physiological peri‐implant soft‐tissue dimensions and factors that may compromise peri‐implant tissue esthetics. Factors such as papilla fill adjacent to the implant and midfacial mucosal height are critical parameters that determine the esthetic success of implant‐supported restorations. Papilla fill adjacent to a single dental implant appears to depend upon the clinical attachment level of the neighboring tooth. A horizontal inter‐implant distance of at least 3 mm is necessary to ensure optimal interproximal mucosal embrasure between two adjacent implants in the anterior maxilla. In cases where implants cannot be placed at least 3 mm apart, a single implant with a cantilever bridge should be considered. Buccolingual implant positioning plays a major role in midfacial mucosal height. Soft‐tissue volume grafting following immediate implant placement in the presence of a thin soft‐tissue phenotype or simultaneous to surgical peri‐implantitis therapy might help to overcome facial mucosa recession.
Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
Authors: Se Jin Oh, Hyo-Jung Lee, Kwon-Ho Song, Suyeon Kim, Eunho Cho, Jaeyoon Lee, Marcus W. Bosenberg, Tae Woo Kim
Journal: Journal of Clinical Investigation (2022)

Immune checkpoint blockade (ICB) therapy has shifted the paradigm for cancer treatment. However, the majority of patients lack effective responses because of the emergence of immune-refractory tumors that disrupt the amplification of antitumor immunity. Therefore, the identification of clinically available targets that restrict antitumor immunity is required to develop potential combination therapies. Here, using transcriptomic data on patients with cancer treated with programmed cell death protein 1 (PD-1) therapy and newly established mouse preclinical anti-PD-1 therapy-refractory models, we identified NANOG as a factor restricting the amplification of the antitumor immunity cycle, thereby contributing to the immune-refractory feature of the tumor microenvironment (TME). Mechanistically, NANOG induced insufficient T cell infiltration and resistance to CTL-mediated killing via the histone deacetylase 1-dependent (HDAC1-dependent) regulation of CXCL10 and MCL1, respectively. Importantly, HDAC1 inhibition using an actionable agent sensitized NANOGhi immune-refractory tumors to PD-1 blockade by reinvigorating the antitumor immunity cycle. Thus, our findings implicate the NANOG/HDAC1 axis as a central molecular target for controlling immune-refractory tumors and provide a rationale for combining HDAC inhibitors to reverse the refractoriness of tumors to ICB therapy.
Corrections
Journal: Gut (1973)

This is a comprehensive textbook of clinical genetics, with contributions from 31 outstanding British and American authorities.An opening section deals with general problems, such as the taking of a family history, pharmacogenetics, im- munogenetics, and lethal and sublethal malformations.Twenty-one chapters are devoted to the genetic aspects of the individual specialities, such as metabolic disorders, the muscles, the central nervous system, the haemopoietic system,
Liquid Biopsy May Guide EGFR Inhibitor Treatment
Journal: Cancer Discovery (2021)

A liquid biopsy may select patients with metastatic colorectal cancer who are good candidates for additional anti-EGFR therapy after developing resistance to it earlier in their treatment regimen. In a phase II trial, patients who received panitumumab based on an absence of resistance mutations in circulating tumor DNA had a 30% response rate to the anti-EGFR agent.
Elements of Surgical Diagnosis.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Initial Findings in Efficacy Evaluation of a Novel Clinical Support Tool: The Food Allergy Passport
Authors: Ashley Ciliberti, Justin Zaslavsky, Lisa Lombard, Waheeda Samady, Alexandria Bozen, Iva Hammitt, Rhea Sharma, Kari Nadeau, Ruchi Gupta, Mary Tobin
Journal: Journal of Allergy and Clinical Immunology (2022)
Pancreas
Authors: G Mantzaris, A Hatzis, E Archavlis, Kal Petraki, S Ladas, G Triantafyllou, S Raptis, C Giannelli, R Paloscia, M Graziani, S Ciarletti, L Carli, M Luminari
Journal: Gut (1994)

3rd UEGW Oslo 1994 A35 per os (1 tablet 100 mg/twice/daily)]; (b) the patients of 2nd group received flucytosine (FCT) [150 mg/kg/daily per os (1 tablet 500 mg/twice/daily)]; (c) the patients of 3rd group received placebo (P) (1 tablet/twice/daily).In order to evaluate the efficacy of pharmacological therapy, clinical ex- amination was performed every week up to the end of follow-up (3 months); endoscopic examination was performed at the end of pharmacological treat- ment (5 weeks).All the patients selected for the study provided informed consent.Results.After 5 weeks of treatment, complete remimission of endoscopic lesions was observed in 14 patients of F-group and in 4 patients of FCT-group (p < 0.05); partial remission of endoscopic lesions was observed in 6 patients of F-group and in 10 patients of FCT-group (p = n.s.), whereas 2 patients of P-group presented partial remission of esophageal lesions.No response was observed in 6 patients of FCT-group and in 18 patients of P-group, with a difference statistically significant in comparison with F-group (p < 0.01 vs FCT-group and p < 0.001 vs P-group).As regards clinical symptomatology, complete remission was observed in 16 patients of F-group and in 12 patients of FCT-group (p = n.s.), with a difference statistically significant for both treatments in comparison with P-group (p < 0.01).Partial clinical remission was observed in 4 patients of F-group in 6 patients of FCT-group (p = n.s.vs F group) and in 6 patients of P-group.No clinical response was observed in 2 patients of FCT-group and in 14 patients of P-group (p < 0.001).No remarkable side-effect has been observed in the patients of both groups of treatment.Conclusions.The results of this study have demonstrated that both F and FCT are efficacious in the treatment of esophageal candidiasis in AIDS patients with a difference statistically significant in comparison with P F demon- strated a greater therapeutic efficacy than FCT, with a difference statisti- cally significant, as regards both endoscopic and clinical response.Neverthe- less, further controlled investigations are needed to improve our knowledges about the therapeutic action of antifungal drugs in the treatment of Candida esophagitis in HIV disease.
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Authors: George C Drosos, Daisy Vedder, Eline Houben, Laura Boekel, Fabiola Atzeni, Sara Badreh, Dimitrios T Boumpas, Nina Brodin, Ian N Bruce, Miguel Ángel González-Gay, Søren Jacobsen, György Kerekes, Francesca Marchiori, Chetan Mukhtyar, Manuel Ramos-Casals, Naveed Sattar, Karen Schreiber, Savino Sciascia, Elisabet Svenungsson, Zoltan Szekanecz, Anne-Kathrin Tausche, Alan Tyndall, Vokko van Halm, Alexandre Voskuyl, Gary J Macfarlane, Michael M Ward, Michael T Nurmohamed, Maria G Tektonidou
Journal: Annals of the Rheumatic Diseases (2022)

Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Methods Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion. Results Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target &lt;130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level &lt;0.36 mmol/L (&lt;6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or urate-lowering therapy in gout has been associated with CVR lowering. Conclusion These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases.
Risk Stratification for Congenital Heart Surgery for ICD-10 Administrative Data (RACHS-2)
Authors: Philip Allen, Farhan Zafar, Junhui Mi, Sarah Crook, Joyce Woo, Natalie Jayaram, Roosevelt Bryant, Tara Karamlou, James Tweddell, Kacie Dragan, Stephen Cook, Edward L Hannan, Jane W Newburger, Emile A Bacha, Robert Vincent, Khanh Nguyen, Kathleen Walsh-Spoonhower, Ralph Mosca, Neil Devejian, Steven A Kamenir, George M Alfieris, Michael F Swartz, David Meyer, Erin A Paul, John Billings, Brett R Anderson
Journal: Journal of the American College of Cardiology (2022)
H pylori is weakly associated with heart disease
Journal: BMJ (1999)

H pylori is weakly associated with heart diseaseChronic infection with Helicobacter pylori may be an avoidable cause of coronary heart disease, but most studies have been too small and prone to bias to assess this reliably.Danesh et al (p 1157) report two of the largest case-control studies so far.A study of 1122 cases of early onset myocardial infarction (average age 44 years) and 1122 age and sex matched controls found that myocardial infarction is about twice as common in people with serological evidence of persistent H pylori infection than in others.A weaker trend was found in a separate study of 510 sibling pairs.The authors conclude that in the context of previously published studies, their results show a weak association between H pylori and early onset heart disease.